Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery, as well as develops CLIA-validated assay to measure FKBP5 gene expression. It is developing relacorilant that is in a Phase II trial to treat patients with Cushing's syndrome; abraxane in combination with relacorilant, which is in Phase I/II open label trial to treat solid tumors; and selective cortisol modulator CORT125281 combined with Xtandi that is in open label Phase I/II trial to treat patients with metastatic castration-resistant prostate cancer. The company is also developing CORT118335 selective cortisol modulator, which is in Phase I/II open label trial for the treatment of antipsychotic-induced weight gain and non-alcoholic steatotic hepatitis. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone650-327-3270
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$159.20 million
Profitability
Miscellaneous
Employees136
OptionableOptionable
Corcept Therapeutics (NASDAQ:CORT) Frequently Asked Questions
What is Corcept Therapeutics' stock symbol?
Corcept Therapeutics trades on the NASDAQ under the ticker symbol "CORT."
How were Corcept Therapeutics' earnings last quarter?
Corcept Therapeutics Incorporated (NASDAQ:CORT) announced its quarterly earnings results on Thursday, November, 1st. The biotechnology company reported $0.14 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.16 by $0.02. The biotechnology company earned $64.45 million during the quarter, compared to analysts' expectations of $67.42 million. Corcept Therapeutics had a net margin of 63.79% and a return on equity of 32.96%. The business's revenue for the quarter was up 50.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.10 earnings per share. View Corcept Therapeutics' Earnings History.
When is Corcept Therapeutics' next earnings date?
What price target have analysts set for CORT?
4 brokerages have issued 12-month price targets for Corcept Therapeutics' shares. Their forecasts range from $11.00 to $32.00. On average, they expect Corcept Therapeutics' share price to reach $17.00 in the next twelve months. This suggests a possible upside of 44.1% from the stock's current price. View Analyst Price Targets for Corcept Therapeutics.
What is the consensus analysts' recommendation for Corcept Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Corcept Therapeutics.
What are Wall Street analysts saying about Corcept Therapeutics stock?
Here are some recent quotes from research analysts about Corcept Therapeutics stock:
- 1. According to Zacks Investment Research, "Corcept is making a good progress with its Cushing's syndrome drug, Korlym. Efforts to expand Korlym’s label are encouraging and should boost the drug’s commercial potential significantly. The company is also attempting to develop its pipeline with its most advanced candidate, relacorilant (CORT125134), which is currently under evaluation in a phase II study for Cushing's syndrome. A successful development of its pipeline candidates will further boost the company’s portfolio and lead to increased sales. However, Corcept’s share price movement shows that the stock has underperformed in the past one year. Moreover, the company is solely dependent on Korlym for growth. Additionally, a decline in Korlym sales will hinder the company’s growth prospects in the future quarters. Estimates have remained stable ahead of the Q4 earnings release. Corcept has a mixed record of earnings surprises in recent quarters." (2/5/2019)
- 2. Cantor Fitzgerald analysts commented, ". We are Neutral on CORT with a 12-month price target of $17 based on value from Korlym. Yesterday, after market close, Corcept reported 3Q18 revenues of $64.4M & cash of $196.7M. Our model projects current cash & Korlym profits to fund operations through the P3 study of Relacorilant in Cushing’s as well as signal-seeking studies underway with several earlier candidates. 3Q call centered on sustainability of Korlym sales growth and Rela’s P3. Korlym sales grew 51% in 3Q18 compared to 3Q17. We believe that this growth is a result of the company’s effective outreach and education efforts to physicians that has yet to peak as there are prescribers it has yet to engage." (11/2/2018)
Has Corcept Therapeutics been receiving favorable news coverage?
Media stories about CORT stock have been trending negative this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Corcept Therapeutics earned a media sentiment score of -2.8 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near term.
Are investors shorting Corcept Therapeutics?
Corcept Therapeutics saw a increase in short interest in January. As of January 31st, there was short interest totalling 25,326,757 shares, an increase of 0.9% from the January 15th total of 25,551,901 shares. Based on an average daily trading volume, of 2,396,637 shares, the days-to-cover ratio is currently 10.6 days. Currently, 24.3% of the company's shares are sold short. View Corcept Therapeutics' Current Options Chain.
Who are some of Corcept Therapeutics' key competitors?
Some companies that are related to Corcept Therapeutics include United Therapeutics (UTHR), Patheon (PTHN), Alkermes (ALKS), FibroGen (FGEN), Array Biopharma (ARRY), GW Pharmaceuticals PLC- (GWPH), TESARO (TSRO), Taro Pharmaceutical Industries (TARO), Amneal Pharmaceuticals (AMRX), Horizon Pharma (HZNP), Agios Pharmaceuticals (AGIO), HUTCHISON CHINA/S (HCM), Evotec (EVTCY), Emergent Biosolutions (EBS) and Intercept Pharmaceuticals (ICPT).
Who are Corcept Therapeutics' key executives?
Corcept Therapeutics' management team includes the folowing people:
- Dr. Joseph K. Belanoff, Co-Founder, CEO, Pres & Director (Age 62)
- Mr. Gary Charles Robb, CFO, Chief Accounting Officer & Sec. (Age 56)
- Mr. Sean Maduck, Sr. VP of Commercial (Age 42)
- Dr. Robert S. Fishman, Chief Medical Officer (Age 57)
- Dr. Hazel Hunt Ph.D., Sr. VP of Research
Who are Corcept Therapeutics' major shareholders?
Corcept Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (13.45%), Dimensional Fund Advisors LP (1.65%), Bank of New York Mellon Corp (1.16%), Northern Trust Corp (1.13%), Geode Capital Management LLC (1.02%) and Principal Financial Group Inc. (0.79%). Company insiders that own Corcept Therapeutics stock include David L Mahoney, G Leonard Baker Jr, Gary Charles Robb, Joseph K Belanoff, Patrick G Enright, Renee D Gala, Robert S Fishman and Sean Maduck. View Institutional Ownership Trends for Corcept Therapeutics.
Which institutional investors are selling Corcept Therapeutics stock?
CORT stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, BlackRock Inc., Oak Ridge Investments LLC, Intellectus Partners LLC, Los Angeles Capital Management & Equity Research Inc., Tealwood Asset Management Inc., Essex Investment Management Co. LLC and Dana Investment Advisors Inc.. Company insiders that have sold Corcept Therapeutics company stock in the last year include G Leonard Baker Jr, Gary Charles Robb, Joseph K Belanoff, Robert S Fishman and Sean Maduck. View Insider Buying and Selling for Corcept Therapeutics.
Which institutional investors are buying Corcept Therapeutics stock?
CORT stock was acquired by a variety of institutional investors in the last quarter, including Oregon Public Employees Retirement Fund, PNC Financial Services Group Inc., D. E. Shaw & Co. Inc., SG Americas Securities LLC, Peregrine Capital Management LLC, AMI Asset Management Corp, Dimensional Fund Advisors LP and Raymond James & Associates. Company insiders that have bought Corcept Therapeutics stock in the last two years include G Leonard Baker Jr, Gary Charles Robb and Renee D Gala. View Insider Buying and Selling for Corcept Therapeutics.
How do I buy shares of Corcept Therapeutics?
Shares of CORT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Corcept Therapeutics' stock price today?
One share of CORT stock can currently be purchased for approximately $11.80.
How big of a company is Corcept Therapeutics?
Corcept Therapeutics has a market capitalization of $1.36 billion and generates $159.20 million in revenue each year. The biotechnology company earns $129.12 million in net income (profit) each year or $0.44 on an earnings per share basis. Corcept Therapeutics employs 136 workers across the globe.
What is Corcept Therapeutics' official website?
How can I contact Corcept Therapeutics?
Corcept Therapeutics' mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-327-3270 or via email at [email protected]
MarketBeat Community Rating for Corcept Therapeutics (NASDAQ CORT)
MarketBeat's community ratings are surveys of what our community members think about Corcept Therapeutics and other stocks. Vote "Outperform" if you believe CORT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CORT will underperform the S&P 500 over the long term. You may vote once every thirty days.
